TMEM158 and prostate cancer: TMEM158 expression was significantly lower in prostate cancer tissues and is associated with disease progression and unfavorable clinicopathologic features such as advanced stage, lymph node invasion, residual tumors after surgery, elevated PSA, higher Gleason scores, lower disease-specific survival, older age, more aggressiveness of the disease.